Visitors of the Dutch drug checking services: Profile and drug use experience.
Raoul Pieter Joost Koning, Annemieke Benschop, Camiel Wijffels, Judith Noijen
International Journal of Drug Policy September 2021 DOI: 10.1016/j.drugpo.2021.103293 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 1,530 |
| Population | Clients of eight participating Dutch drug checking services (Drug Information and Monitoring System, DIMS) in the Netherlands in 2018 |
| Topics | MDMA |
| Keywords | Drug checking Drug safety testing Drug testing Harm reduction |
| Key findings | Dutch drug checking clients were mostly highly educated men in their twenties with no migration background, and nearly all had prior drug experience: only 0.7% had never used any of the twenty drugs studied, and 93% reported ecstasy or MDMA use (average 6.3 years since first use). The authors argue drug checking can help public health services reach people who use drugs and is unlikely to encourage initiation, but may not be accessible to all demographic groups. |
Abstract
Drug checking services (DCS) provide information about drug content and purity, alongside personalized feedback, to people who use drugs; however, the demographic and drug use characteristics of DCS clients are rarely reported. This paper describes these characteristics for clients of the Dutch DCS, the Drug Information and Monitoring System (DIMS). 1,530 participants completed a pen-and-paper questionnaire at one of eight participating DCS in the Netherlands in 2018. The participants were mostly highly educated males in their twenties with no migration background. Experience with drugs prior to coming to the DCS was common. Only 0.7% indicated they had never used any of the twenty drugs studied. 93% of participants reported use of ecstasy or MDMA with an average of 6.3 years since first use. These results indicate that drug checking can be a valuable tool for public health services as it facilitates access to more difficult-to-reach communities who use drugs. It is unlikely that DCS encourage drug initiation, since almost all people who visit the Dutch DCS already report experience with drugs. However, DCS should be aware that their services might not be easily accessible or attractive to all demographic groups.
Comparable studies
Other cross-sectional and survey studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug Recreational Ecstasy users recruited via snowball peer network | 1992 | Cross-sectional survey | n = 100 |
| Reducedin vivobinding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users Male regular ecstasy users and well-matched controls | 1999 | Cross-sectional association study | n = 20 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Patterns of recreational drug use at dance events in Edinburgh, Scotland Drug users at dance events in Edinburgh, Scotland, UK, aged 16-47, 80% between 18 and... | 2001 | Cross-sectional survey | n = 122 |
| Acute, sub‐acute and long‐term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users Regular MDMA users | 2003 | Cross-sectional study | n = 466 |
Citations in the library
Cited by 5
- Comparison of strength and adulteration between illicit drugs obtained from cryptomarkets versus off-line. Addiction 2025
- NPAideS: a drug-checking study among 3-methylmethcathinone (3-MMC) users. Harm Reduction Journal July 28, 2023
- Recreational drug poisonings reported to six European poison centres from 2021 to 2024 Clinical Toxicology March 4, 2026
- Size matters: comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012–2021 Drugs, Habits and Social Policy November 24, 2022
- Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. International Journal of Drug Policy February 2022